Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema

Francesco Bandello1, Umberto De Benedetto1, Karl Anders Knutsson1, Maurizio Battaglia Parodi1, Maria Lucia Cascavilla1, Pierluigi Iacono21Department of Ophthalmology, University Vita-salute, Scientific Institute San Raffaele, Milan, Italy; 2Fondazione G B Bietti per l&rsquo;Oftalmologia, IRC...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bandello F, De Benedetto U, Knutsson KA, Battaglia Parodi M, Cascavilla ML, Iacono P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/873eb95a24d949748b2783f8ffcf9694
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:873eb95a24d949748b2783f8ffcf9694
record_format	dspace
spelling	oai:doaj.org-article:873eb95a24d949748b2783f8ffcf96942021-12-02T04:40:28ZRanibizumab in the treatment of patients with visual impairment due to diabetic macular edema1177-54671177-5483https://doaj.org/article/873eb95a24d949748b2783f8ffcf96942011-09-01T00:00:00Zhttp://www.dovepress.com/ranibizumab-in-the-treatment-of-patients-with-visual-impairment-due-to-a8280https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Francesco Bandello1, Umberto De Benedetto1, Karl Anders Knutsson1, Maurizio Battaglia Parodi1, Maria Lucia Cascavilla1, Pierluigi Iacono21Department of Ophthalmology, University Vita-salute, Scientific Institute San Raffaele, Milan, Italy; 2Fondazione G B Bietti per l&rsquo;Oftalmologia, IRCCS, Rome, ItalyAbstract: Diabetic macular edema is the major cause of visual acuity impairment in diabetic patients. The exact etiopathogenesis is unknown and, currently, grid/focal retinal laser photocoagulation represents the recommended treatment. It has been demonstrated that vascular endothelial growth factor (VEGF) plays a key role in the pathogenesis of diabetic macular edema by mediating vascular permeability and accumulation of intracellular and extracellular fluid, and thereby represents an appealing candidate as a therapeutic target for the treatment of diabetic macular edema. The advent of intravitreal anti-VEGF drugs has opened up a new era for the management of diabetic macular edema. At present, three anti-VEGF substances are available for routine clinical use, ie, pegaptanib, ranibizumab, and bevacizumab. The aim of this review is to summarize the evidence supporting the use of ranibizumab in clinical practice. Most of the studies analyzed in this review are prospective, controlled clinical trials that have focused on documenting the therapeutic effect of ranibizumab and its safety, providing encouraging results.Keywords: ranibizumab, diabetic macular edema, anti-VEGF, diabetic macular edemaBandello FDe Benedetto UKnutsson KABattaglia Parodi MCascavilla MLIacono PDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2011, Iss default, Pp 1303-1308 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Bandello F De Benedetto U Knutsson KA Battaglia Parodi M Cascavilla ML Iacono P Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema
description	Francesco Bandello1, Umberto De Benedetto1, Karl Anders Knutsson1, Maurizio Battaglia Parodi1, Maria Lucia Cascavilla1, Pierluigi Iacono21Department of Ophthalmology, University Vita-salute, Scientific Institute San Raffaele, Milan, Italy; 2Fondazione G B Bietti per l&rsquo;Oftalmologia, IRCCS, Rome, ItalyAbstract: Diabetic macular edema is the major cause of visual acuity impairment in diabetic patients. The exact etiopathogenesis is unknown and, currently, grid/focal retinal laser photocoagulation represents the recommended treatment. It has been demonstrated that vascular endothelial growth factor (VEGF) plays a key role in the pathogenesis of diabetic macular edema by mediating vascular permeability and accumulation of intracellular and extracellular fluid, and thereby represents an appealing candidate as a therapeutic target for the treatment of diabetic macular edema. The advent of intravitreal anti-VEGF drugs has opened up a new era for the management of diabetic macular edema. At present, three anti-VEGF substances are available for routine clinical use, ie, pegaptanib, ranibizumab, and bevacizumab. The aim of this review is to summarize the evidence supporting the use of ranibizumab in clinical practice. Most of the studies analyzed in this review are prospective, controlled clinical trials that have focused on documenting the therapeutic effect of ranibizumab and its safety, providing encouraging results.Keywords: ranibizumab, diabetic macular edema, anti-VEGF, diabetic macular edema
format	article
author	Bandello F De Benedetto U Knutsson KA Battaglia Parodi M Cascavilla ML Iacono P
author_facet	Bandello F De Benedetto U Knutsson KA Battaglia Parodi M Cascavilla ML Iacono P
author_sort	Bandello F
title	Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema
title_short	Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema
title_full	Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema
title_fullStr	Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema
title_full_unstemmed	Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema
title_sort	ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/873eb95a24d949748b2783f8ffcf9694
work_keys_str_mv	AT bandellof ranibizumabinthetreatmentofpatientswithvisualimpairmentduetodiabeticmacularedema AT debenedettou ranibizumabinthetreatmentofpatientswithvisualimpairmentduetodiabeticmacularedema AT knutssonka ranibizumabinthetreatmentofpatientswithvisualimpairmentduetodiabeticmacularedema AT battagliaparodim ranibizumabinthetreatmentofpatientswithvisualimpairmentduetodiabeticmacularedema AT cascavillaml ranibizumabinthetreatmentofpatientswithvisualimpairmentduetodiabeticmacularedema AT iaconop ranibizumabinthetreatmentofpatientswithvisualimpairmentduetodiabeticmacularedema
_version_	1718401132977455104

Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema

Ejemplares similares